MCK
McKesson Corporation
Is MCK Halal?
Pharmaceutical distribution with a generally permissible healthcare core; MSCI receivables-plus-cash screen fails.
What You Should Know
McKesson distributes medicines, medical supplies and healthcare technology. Debt/assets are 7.93%, liquidity is 4.83%, receivables plus cash are 38.85% and disclosed interest income is 0.04% of fiscal revenue; product and customer activity remains incompletely disclosed.
⚠️ Concerns
- •Receivables plus cash/assets are 38.85% and exceed the examined MSCI total-assets limit
- •CVS represented approximately 24% of fiscal revenue and top ten customers 73%
- •Controlled-substance distribution and historical opioid litigation require review
- •Interest income is $179 million; finance charges and late fees need scholar-specific treatment
- •Physician-practice finance leases and customer payment terms require review
- •Drug shortages, recalls, pricing, privacy and supply-chain resilience require continuing review
Current quantitative Sharia screen
Based on 10-K figures for the period ended 2026-03-31; calculated 2026-07-13.
6,526 / 82,323
3,975 / 82,323
31,960 / 82,323
179 / 403,430
- Financial
- Pass
- Overall
- Incomplete
Debt is 7.93%, liquidity is 4.83%, receivables plus cash are 38.85% and disclosed interest income is 0.04%; each is below the examined FTSE limits. Business activity remains incomplete because the filing does not quantify a universal prohibited-revenue numerator.
- Financial
- Fails
- Overall
- Fails
Debt is 7.93% and liquidity is 4.83%, but receivables plus cash are 38.85%, above the examined MSCI total-assets 33.33% limit. This is a calculation against the named method, not an index-membership claim; business allocation remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt is 7.93% and liquidity is 4.83%, below the examined 33% Malaysia SAC financial limits. This is a calculation against SAC ratios, not an official classification of a U.S.-listed security; screened business revenue remains unavailable.
- Financial
- Not calculated
- Overall
- Not calculated
A properly licensed and reproducible historical market-cap series is not stored, so these methods are not estimated from a current spot price.
Business-activity disclosure
McKesson distributes branded, generic, specialty and over-the-counter pharmaceuticals, medical supplies and healthcare technology and provides oncology, pharmacy and practice solutions. Healthcare logistics and medicines distribution are generally permissible commerce, while controlled-substance distribution, finance leases, late fees and customer end uses require qualitative review.
Limitation: The filing reports segment revenue and product/service categories but does not quantify a universal prohibited-revenue numerator by controlled substance, alcohol-containing product, payer, government contract, pharmacy, oncology treatment, finance lease or other end use.
Purification
McKesson discloses $179 million of interest income, or 0.04% of fiscal revenue, but does not quantify every finance charge, controlled-substance, product or customer end use. No fixed purification percentage is prescribed here; readers should follow the scholar or methodology they use.
Inputs, assumptions and primary sources
- Debt uses $6.526 billion of total debt outstanding at March 31, 2026, including current maturities and finance-lease obligations; operating lease obligations are not entered as conventional debt.
- Cash uses $3.975 billion of cash and cash equivalents. The filing says cash equivalents are primarily AAA-rated U.S. government money-market funds, short-term deposits and commercial paper issued by non-financial institutions; these are not added again as separate securities.
- Receivables use $27.985 billion of net receivables, primarily trade accounts receivable from customers and amounts due from suppliers. Physician-practice finance leases are disclosed separately and are not treated as a lending arm here.
- Revenue uses $403.430 billion for fiscal 2026 across pharmaceutical distribution, oncology and multispecialty, prescription technology and medical-surgical solutions.
- The filing discloses $179 million of interest income for fiscal 2026 and separately notes that finance charges to customers, primarily late fees, are included in other income. Only the disclosed interest-income line is used for the income screen.
- McKesson distributes medicines, medical supplies and healthcare technology, but the filing does not quantify every controlled-substance, payer, pharmacy, government, oncology or customer end use into a universal prohibited-revenue numerator.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →